Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics
Published: 02 Apr 2026
Author: Precedence Research
Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics
Gallant is an animal health biotechnology company that has announced a landmark partnership with MWI Animal Health to establish the first ultra-low-temperature cold chain for veterinary medicine. As Gallant advances toward delivering the potential first-ever FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional approval by the U.S. Food and Drug Administration, Centre for Veterinary Medicine.
The first expected product, Sonruvetcel injectable suspension, from Gallant’s pipeline, has potential as a first-in-class, uterine-derived allogeneic mesenchymal stromal cell (MSC) therapy for cats with refractory feline chronic gingivostomatitis (rFCGS).
Market growth is driven by Stem cell therapy in Veterinary.
According to Towards Healthcare, the Veterinary stem cell therapy market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 933.46 million in 2026 to approximately USD 2034.08 million by 2035, representing a compound annual growth rate (CAGR) of 9.04% from 2026 to 2035. Growth is driven by the growing incidence of chronic illnesses in animals, adopting the cutting-edge therapeutic options and using the stem cells' capacity for regeneration to restore damaged tissues and organs in a variety of animal species, such as dogs, cats, horses, and even exotic animals.
CEO of Gallant DVM, Ph.D Dr. Linda Black said Breakthrough science only matters if we can safely and reliably put it into the hands of veterinary professionals. Partnership with MWI ensures that veterinarians can conveniently access an FDA-regulated, off-the-shelf stem cell therapy with confidence in its quality and integrity.
The agreement is signed with MWI to develop and deploy a scalable, ultra-low temperature model. This support is provided nationwide across the continental United States and in non-contiguous U.S. markets, including Alaska, Hawaii, and Puerto Rico.
Expanding the Spectrum of Care
Gallant, in collaboration with the American Animal Hospital Association, discovered that veterinary professionals believe stem cell therapy will become a standard treatment option for the next decade.
Partnership betweenGallant–MWI directly addresses veterinary professionals with expectations and practices that meet the needs by pairing an anticipated FDA-regulated derived stem cell therapy with a clinic-friendly model.
About Gallant
It has explored a new category of veterinary medicine with a pipeline of off-the-shelf, ready-to-use stem cell therapies for the root causes of disease in pets. Deep expertise in the veterinary regenerative method in development, manufacturing, and commercialization, making medicine accessible for daily practise.
A recent report by Towards Healthcare highlights that the Veterinary stem cell therapy Market is witnessing significant growth, driven by increasing chronic conditions in pets, advancements in regenerative medicine, rising pet humanization, and a greater willingness among owners to invest in advanced treatments.